Login
$ADCT
$1.25 +$0.00 (0.0%) After hours

$ADCT 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Results of Operations and Financial Condition

Third quarter 2026 net product revenue of $21 million; cash and cash equivalents of $189.2 million as of September 30, 2026

04 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more

ZYNLONTA data to be featured across 5 oral presentations and multiple posters

13 Oct 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October 7, 2026, by and between ADC Therapeutics SA, a société anonyme domiciled in Epalinges, Canton of Vaud, Switzerland, and organized under the laws of Switzerland ...

13 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026

02 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

On June 30, 2026, the Board of Directors of ADC Therapeutics SA (the “Company”), with the advice of its independent compensation consultant, approved one-time retention awards (“Awards”) to certain of the Company’s employees, including i...

24 Jun 2026 8-K: Regulation FD Disclosure; Other Events

Planned 17% workforce reduction expected to generate annualized estimated savings of approximately $10m, enhancing financial flexibility

03 Jun 2026 8-K: Regulation FD Disclosure; Other Events

Forward - Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing con...

02 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

Section 1 Name, Registered Office, Purpose and Duration of the Company

04 May 2026 8-K: Results of Operations and Financial Condition

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year end

10 Mar 2026 8-K: Results of Operations and Financial Condition

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026

23 Feb 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWIS...

12 Jan 2026 8-K: Regulation FD Disclosure

2 Forward - Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing c...

08 Jan 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates

05 Dec 2025 8-K: Other Events

On December 3, 2025, ADC Therapeutics SA (the “Company”) announced updated data from the ongoing LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofi...

10 Nov 2025 8-K: Results of Operations and Financial Condition

Continued progress across LOTIS-7 with updated data anticipated in 2025 and LOTIS-5 with topline data expected in 1H 2026

14 Oct 2025 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October 12, 2025, by and between ADC Therapeutics SA, a société anonyme domiciled in Epalinges, Canton of Vaud, Switzerland, and organized under the laws of Switzerland...

30 Sep 2025 8-K: Regulation FD Disclosure

Forward - Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing con...

12 Aug 2025 8-K: Results of Operations and Financial Condition

ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% in LOTIS-7 across 30 efficacy evaluable patients

12 Jun 2025 8-K: Entry into a Material Definitive Agreement; Costs Associated with Exit or Disposal Activities +1 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of June 11, 2025, by and between ADC Therapeutics SA, a société anonyme domiciled in Epalinges, Canton of Vaud, Switzerland, and organized under the laws of Switzerland (t...

05 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

Section 1 Name, Registered Office, Purpose and Duration of the Company

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support